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Abstract
Posttransplantation diabetes mellitus (PTDM) is a frequent complication in immunosuppressive therapy. To better
understand the molecular events associated with PTDM we investigated the effect of cyclosporine on expression and
activity of hepatic nuclear factor (HNF)1alpha and 4alpha and on genes coding for glucose metabolism in cultures of the rat
insulinoma cell line INS-1E, the human epithelial cell line Caco-2 and with Zucker diabetic fatty (ZDF) rats. In the pancreas of
untreated but diabetic animals expression of HNF4alpha, insulin1, insulin2 and of phosphoenolpyruvate carboxykinase was
significantly repressed. Furthermore, cyclosporine treatment of the insulinoma-1E cell line resulted in remarkable reduction
in HNF4alpha protein and INS1 as well as INS2 gene expression, while transcript expression of HNF4alpha, apolipoprotein
C2, glycerolkinase, pyruvatekinase and aldolase B was repressed in treated Caco-2 cells. Furthermore, with nuclear extracts
of cyclosporine treated cell lines protein expression and DNA binding activity of hepatic nuclear factors was significantly
repressed. As cyclosporine inhibits the calcineurin dependent dephosphorylation of nuclear factor of activated T-cells
(NFAT) we also searched for binding sites for NFAT in the pancreas specific P2 promoter of HNF4alpha. Notably, we
observed repressed NFAT binding to a novel DNA binding site in the P2 promoter of HNF4alpha. Thus, cyclosporine caused
inhibition of DNA binding of two important regulators for insulin signaling, i.e. NFAT and HNF4alpha. We further
investigated HNF4alpha transcript expression and observed .200-fold differences in abundance in n=14 patients. Such
variability in expression might help to identify individuals at risk for developing PTDM. We propose cyclosporine to repress
HNF4alpha gene and protein expression, DNA-binding to targeted promoters and subsequent regulation of genes coding
for glucose metabolism and of pancreatic beta-cell function.
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Introduction
In organ transplantation there is a need to suppress an immune
response against the grafted organ. Immunosuppressive therapies
with calcineurin inhibitors result, however, in unwanted secondary
effects. This includes risk of infections of all types, lymphomas and
other malignancies [1,2]. Posttransplantion diabetes mellitus
(PTDM) is a further complication with an incidence of
approximately 8–10% for cyclosporine and 16–18% for tacrolimus
across renal, liver, heart and lung transplant patients [3,4].
Noteworthy, the DIRECT study reports a 36% incidence of
impaired glucose metabolism and a 14% incidence of PTDM with
either cyclosporine or tacrolimus [5]. Indeed, cyclosporine caused
morphologic and functional alterations of pancreatic beta-cells
with subsequent hyperglycemia and hypoinsulinoma in diverse
animal studies [6–11]. Based on their mode of action cyclosporine
and tacrolimus repress interleukin-2, thereby suppressing the early
cellular response of T-lymphocytes to an antigenic stimuli. As of
today the causes for the diabetogenic potential of calcineurin
inhibitors remain uncertain. To better understand the molecular
events associated with PTDM we investigated expression and
activity of hepatic nuclear factor 1a (HNF1a) and 4a (HNF4a).
Notably, dysfunction of these transcription factors have been
associated with diabetes mellitus. For instance, the early onset of
type II diabetes referred to as MODY (maturity onset diabetes of
the young) was mapped to mutations within the HNF1a (MODY3)
and HNF4a (MODY1) gene [12]. Moreover, linkage analysis in
combination with fine-mapping for susceptibility to multifactorial
late-onset type 2 diabetes has identified predisposing variants of
HNF4a and HNF1a in a growing number of studies [13–15]. The
HNF4a-dependent transcription of HNF1a is required for normal
b-cell function [16], but there is also a feedback loop of HNF4a
and HNF1a to maintain tissue specific metabolic function [16–
18]. Additionally, in conditional HNF4a knockout mice b-cell
function was impaired upon glucose-stimulated insulin secretion
[19–21] whereas HNF1a knockout mice develop diabetes [22].
Taken collectively, HNF1a and HNF4a regulate various
members of the glucose-dependent insulin secretory pathways
[19–28] and might therefore provide a molecular rational for
calcineurin inhibitor induced diabetes.
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Initially, we investigated expression of HNF4a in the pancreas of
Zucker diabetic fatty (ZDF) rats. This is an established disease
model for type 2 diabetes. We observed reduced expression of
HNF4a and of genes regulated by this factor in the glucose
metabolic pathway, notably phosphoenolpyruvate carboxykinase 1
(PCK1), insulin1 (INS1) and insulin2 (INS2) (Table 1). Furthermore,
HNF4a and HNF1a was significantly reduced in the liver of these
animals (Table 1). In the past HNF4a was shown to regulate INS1
[29]. As rodents express two isoforms of insulin (INS1 and INS2)
[30] both genes were investigated, but the physiological role of
INS2 is not clear as yet [30]. By use of advanced bioinformatics we
identified a new HNF4a binding site in the promoter of the INS2
gene at position 2245 to 2232 upstream of the start site of
transcription [see Material and Methods for sequence information
and electrophoretic mobility shift (EMSA) assay in Fig. 1D]. Loss
of HNF4a DNA-binding to targeted promoters resulted in
reduced expression of genes coding for glucose transport and
metabolism and of insulin secretion from pancreatic ß-cells [28].
Furthermore, in conditional HNF4a knockout mice b-cell function
was impaired upon glucose-stimulated insulin secretion [19–21].
Conversely, in HNF1a overexpressing beta cell lines increased
transcript expression of insulin, glucose transporter 2, L-pyruvate
kinase, and aldolase B was observed [26,27] whereas HNF1a
knockout mice developed diabetes [22].
To further probe for HNF4a and HNF1a function we cultured
the human intestinal cell line Caco-2. This cell line enables
mechanistic studies with HNF4a protein expression being
comparable to its expression levels in the liver [31]. In cell culture
experiments we analyzed the effect of cyclosporine on HNF4a and
HNF1a expression and activity. HNF4a gene and protein
expression (Table 2, Fig 1A) as well as HNF1a protein expression
(Fig 1B) was significantly repressed after treatment of Caco-2 cells
with 25 mM (30 mg/ml) cyclosporine for 72 h, but HNF1a gene
expression remained unchanged (Table 2). For comparison actin
western blotting was used as housekeeping protein (Fig. 1C).
Additionally, we investigated expression of genes coding for
glucose metabolism, i.e. apolipoprotein C2 (ApoC2), aldehyde
dehydrogenase 2 (ALDH2), phosphoenolpyruvate carboxykinase 1
(PCK1), glycerol kinase (GK), pyruvate kinase (PKLR) and aldolase
B( ALDOB), and found ApoC2, GK, PKLR and ALDOB transcripts to
be significantly repressed (Table 2). We further studied the ability
of HNF4a to bind to promoter sequences of HNF1a, ApoC2, GK,
PKLR, ALDOB, and INS2 by EMSA supershift assays. As shown in
Fig. 1D we observed strong binding of nuclear extracts of
untreated cell cultures to all cognate recognition sites. Addition
of a specific HNF4a antibody shifted the band, therefore providing
clear evidence for the specificity of the assay. Strikingly,
cyclosporine reduced binding of HNF4a to all EMSA probes
employed to approximately 20% when compared with untreated
cell cultures (Fig 1D, 1E). Binding activity of HNF1a to its
recognition site in the pancreas specific P2 promoter of HNF4a
was reduced as well (Fig. 2A, 2B), but treatment with equimolar
concentrations of the calcineurin inhibitor tacrolimus did not
influence HNF4a gene expression (Table 3).
To further confirm cyclosporine mediated dysregulation of
HNF4a we analyzed different rat and mouse beta cell lines, i.e.
INS-1E, RINm5F and MIN6 cells, for its HNF4a expression. INS-
1E cells express HNF4a more abundantly and therefore were used
for subsequent experiments (Table 4). As INS-1E cells are much
more sensitive to the cyclosporine induced toxicity effects than
Caco-2 cells, cell viability was tested at different cyclosporine
concentrations. Treatment of INS-1E cells with 8.3 mM (10 mg/
ml) cyclosporine (one third of the concentration used for Caco-2
cells) resulted in a 55% viability (Fig. 3A). In western blotting
experiments actin served as a housekeeping protein, which we
found to be constantly expressed (Fig. 3B). HNF4a protein
expression of INS-1E cells is much lower than in liver [32]. In
nuclear protein extracts HNF4a expression was below the limit of
detection but its gene expression was unchanged (Table 5).
Nonetheless, HNF4a DNA binding activity could be assayed for in
EMSA supershift assays and was significantly reduced to 58% after
treatment with 8.3 mM (10 mg/ml) cyclosporine (Fig. 3C, 3D). It is
of considerable importance that the gene expression of the HNF4a
target genes insulin1 (INS1) and insulin2 (INS2) was significantly
repressed (Table 5).
Taken collectively, HNF4a and HNF1a expression and DNA-
binding activity was repressed after cyclosporine treatment as was
transcription of genes in the glucose and insulin signaling pathways
targeted by HNF4a and HNF1a. Our study is the first report to
determine a direct connection between cyclosporine treatment and
activity of hepatic nuclear factors and our findings provide a
molecular rational for PTDM observed in transplant patients. We
suggest individual differences in the HNF4a gene and protein
expression amongst patients to be of critical importance for the
diabetogenic potential of cyclosporine. Indeed, on average 1/10 of
cyclosporine treated patients develop PTDM. Consequently,
repression of HNF4a by cyclosporine depends on the abundance
of HNF4a protein. In Fig. 4 HNF4a gene expression in the liver of
14 patients was plotted; the data are scattered over a wide range.
Likely, patients with low HNF4a and HNF1a protein would be at
higher risk of developing cyclosporine induced PTDM. Specifi-
cally, cyclosporine binds to calcineurin and inhibits Ca
2+-
dependent serine / threonine phosphatase activity [33]. Normally
this phosphatase dephosphorylates nuclear factor of activated T-
cells (NFAT), which moves from the cytoplasm to the nucleus to
Table 1. Regulation of HNF4a and its target genes in Zucker
diabetic fatty (ZDF) rats.
Gene Organ Treatment Mean6SD
%o ft h e
control p-value
HNF4a Pancreas Control 0.01360.002
ZDF 9 months 0.00860.004 61.5 0.0494
PCK1 Pancreas Control 0.85760.849
ZDF 9 months 0.36560.541 42.6 0.0191
INS1 Pancreas Control 0.14660.076
ZDF 9 months 0.10960.217 74.5 0.0126
INS2 Pancreas Control 0.96060.487
ZDF 9 months 0.45660.871 47.5 0.0052
HNF1a Liver Control 1.37960.611
ZDF 14 weeks 0.83560.365 60.6 0.0494
HNF4a Liver Control 1.18060.330
ZDF 14 weeks 0.69460.228 58.8 0.0015
Gene expression was measured by real-time qRT-PCR in 14 weeks and 9 months
old ZDF rats and lean controls (n=10 animals, respectively) and was
determined relative to expression of cyclophilin, which served as a
housekeeping gene. Gene expression in control rats was set to 100 and values
for ZDF rats represent transcript abundance relative to control. Non-parametric
Mann-Whitney-U-Test was used to compare ZDF and control groups. Results
are considered significant at p,0.05 (gene names and p-values in bold). Gene
expression of HNF4a in the liver of this cohort of ZDF rats has been previously
reported [43].
doi:10.1371/journal.pone.0004662.t001
HNF4alpha and Cyclosporine
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interleukin-2, granulocyte macrophage colony stimulating factor
(GM-CSF), TNFa, IFNc and other interleukins [34,35]. Although
inhibition of calcineurin results in immunosuppression, altering
activity of NFAT will also impact regulation of INS1 gene
transcription. Indeed, this factor is activated by calcineurin in
response to increased Ca
2+-levels [36]. Disruption of the NFAT/
insulin pathway may contribute to the diabetogenic effects of
cyclosporine as will be discussed below. Notably, Heit et al [37]
reported the b-cell specific deletion of calcineurin to result in age-
dependent diabetes, while conditional expression of activated
NFAT reverted the diabetic phenotype in these mice. Further-
more, expression of genes critical for b-cell endocrine function e.g.
HNF4a and HNF1a was increased in mice when NFATc1 was
conditionally activated [37]. It is of considerable importance that
NFAT cooperates with other transcription factors involved in
insulin transcription such as PDX1, NEUROD1 and HNF4a. The
evidence for this cooperation stems from chromatin immunopre-
cipitation assays [37]. The calcineurin/NFAT signaling appears to
be essential for the regulation of pancreatic b-cell function; its
cooperation with HNF4a could provide a molecular rational for
cyclosporine induced PTDM [37]. HNF4a activity differs amongst
cell types, in part due to use of alternate promoters. Whilst in
hepatocytes the P1 promoter of HNF4a is primarily activated, the
P2 promoter is specifically activated in pancreatic b-cells [17,18]
Indeed, P2 is exclusively expressed in INS-1E cells, see Table 6. In
the study of Heit et al [37] binding of NFAT to the P1 promoter of
HNF4a (NM_008261) was observed. The findings of Heit et al
[37] are surprising as for normal b-cell function usage of the P2
promoter of HNF4a would have been expected. Notably, we
observed NFAT binding at the human P2 promoter of HNF4a at
position 2461 to 2450 upstream of the start site of transcription
(see Material and Methods for sequence information). Further-
more, binding of NFAT to the HNF4a P2 promoter was reduced
in response to cyclosporine treatment (Fig. 5A, 5B), but expression
of members of the NFAT gene family (NFATc1, c2, c3, c4) and of
calcineurin itself was unchanged after cyclosporine treatment of
Caco-2 cells (Table 2). There is clear evidence for a role of NFAT
in glucose/insulin homoeostasis [38]. NFAT signaling plays an
essential role in the development of diabetes in calcineurin knock-
out mice [37]. Taken collectively, we report a remarkable
repression of HNF4a and HNF1a after cyclosporine treatment
and propose cyclosporine to act through a calcineurin/NFAT
dependent mechanism on these transcription factors. We further
identified a novel NFAT binding site in the human HNF4a P2
promoter and report HNF4a activity and expression of genes of
the glucose/insulin signaling pathway to be reduced in the
pancreas of ZDF diabetic rats.
In conclusion, cyclosporine repressed HNF4a/HNF1a expres-
sion, DNA-binding to targeted promoters and subsequent
expression of genes involved in glucose metabolism and pancreatic
b-cell function. We propose a molecular mechanism for PTDM
based on dysregulation of HNF4a/HNF1a and of NFAT insulin
signaling pathway targeted by cyclosporine.
Materials and Methods
Cell culture and cyclosporine treatment
Caco-2 cells, a human intestinal cell line derived from a colon
adeno-carcinoma, were obtained from and cultivated as recom-
Figure 1. Cyclosporine inhibits protein expression of HNF4a and binding to target gene promoters. (A) HNF4a western blotting of
20 mg Caco-2 cell nuclear extracts [control or cyclosporine treatment, 25 mM (30 mg/ml) for 72 h]. (B) HNF1a western blotting of 30 mg Caco-2 cell
nuclear extracts [control or cyclosporine treatment, 25 mM (30 mg/ml)for 72 h] (C) Actin western blotting of 15 mg Caco-2 cell nuclear extracts [control
or cyclosporine treatment, 25 mM (30 mg/ml) for 72 h]. The lower panels represent the quantification of protein amounts for HNF4a (A) and HNF1a (B)
relative to the actin expression. (D) Electrophoretic mobility shift assays with 2,5 mg Caco-2 cell nuclear extract [control or cyclosporine treatment,
25 mM (30 mg/ml) for 72 h] and
32P labeled oligonucleotides to probe for DNA binding to HNF4a binding-sites within promoters of HNF1a (HNF1a),
apolipoprotein C2 (ApoC2), glycerol kinase (GK), pyruvate kinase (PKLR), aldolase B (ALDOB), and insulin2 (INS2). In EMSA supershift assays an
antibody directed against HNF4a (+) was added. Shifted (HNF4a) and supershifted bands (HNF4a ss) were marked. (E) Dried EMSA gels were analyzed
with a Molecular Imager (BioRad, Muenchen, Germany) using the Quantity One software (BioRad, Muenchen, Germany). HNF4a binding of control
extracts to the respective binding sites was set to 100% and inhibition of binding to the respective binding sites after treatment with cyclosporine
[25 mM (30 mg/ml) for 72 h] was quantified.
doi:10.1371/journal.pone.0004662.g001
Table 2. Regulation of gene expression in Caco-2 cells after
cyclosporine treatment.
Gene Treatment Mean6SD % of the controlp-value
HNF4a Control 0.69860.060
Cyclosporine 0.26760.008 38.3 0.0495
HNF1a Control 0.91060.094
Cyclosporine 0.96860.069 106.4 0.5127
ApoC2 Control 1.10560.066
Cyclosporine 0.60160.251 54.4 0.0495
ALDH2 Control 0.50360.167
Cyclosporine 0.53960.063 107.2 0.8273
PCK1 Control 1.05660.136
Cyclosporine 0.84060.266 79.5 0.2753
GK Control 0.64760.231
Cyclosporine 0.25160.098 38.8 0.0495
PKLR Control 0.78460.229
Cyclosporine 0.29060.126 37.0 0.0495
ALDOB Control 0.20460.067
Cyclosporine 0.03560.025 17.2 0.0495
NFATc1 Control 0.44960.236
Cyclosporine 0.49860.065 110.9 0.5127
NFATc2 Control 0.65560.193
Cyclosporine 0.49560.196 75.6 0.5127
NFATc3 Control 1.15460.260
Cyclosporine 0.93860.134 81.3 0.2752
NFATc4 Control 0.97460.251
Cyclosporine 0.79360.151 81.4 0.2752
Calcineurin Control 1.23460.222
Cyclosporine 0.90660.533 73.3 0.5127
Gene expression was measured by RT-PCR in Caco-2 cells 72 h after treatment
with 25 mM( 3 0mg/ml) cyclosporine (n=3, respectively) and was determined
relative to expression of mitATPase6, which served as a housekeeping gene.
Gene expression in untreated Caco-2 cells was set to 100 and values for
cyclosporine treatment represent transcript abundance relative to control. Non-
parametric Mann-Whitney-U-Test was used to compare cyclosporine treated
and control groups. Results are considered significant at p,0.05 (gene names
and p-values in bold).
doi:10.1371/journal.pone.0004662.t002
HNF4alpha and Cyclosporine
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und Zellkulturen GmbH, Braunschweig, Germany). INS-1E cells
(rat beta cells derived from insulinomas) were kindly provided by
C. Wollheim (University Medical Center, Geneva, Switzerland)
[39], MIN6 cells (mouse beta cells transgenic for SV40 large T
antigen) were kindly provided by J. Miyazaki (Osaka University
Medical School, Japan) [40] and RIN-m5F cells (rat beta cells
derived from islet cell tumor) were kindly provided by S. Lenzen
(Medical School Hannover, Germany) [41]. Caco-2 cells were
daily treated with 25 mM (30 mg/ml) and INS-1E cells with
8.3 mM (10 mg/ml) cyclosporine (Sandimmun, Novartis, Nu ¨rn-
berg, Germany) for 72 h. Treatment started at 40–50%
confluence. Cell viability was analyzed in triplicate using a MTS
cytotoxicity assay according to the manufacturers instructions
(#G3582, Promega, Mannheim, Germany).
Diabetic disease model
Pancreas (animals aged 9 months) and liver (animals aged 14
weeks) of fa/fa obese Zucker diabetic fatty (ZDF) rats and of +/fa
lean nondiabetic control rats were kindly provided by W. Linz and
H. Ruetten (Sanofi-Aventis, Frankfurt, Germany) [42]. Pancreatic
mRNA degrades quickly, i.e. in less than 1 minute after tissue
resection, therefore, pancreas was frozen immediately. All rats
were male with mean body weight of 398.8630.2 (obese) and
334.2619.3 (lean) for 14 weeks aged animals and 403.8635.7
(obese) and 463.3630.3 (lean) for 9 months aged animals.
Representative phenotype data (e.g. blood glucose, insulin) are
provided in Niehof et al [43].
Isolation of nuclear extracts, western blotting analysis
and electrophoretic mobility shift assays
Nuclear extracts were isolated by the method of Dignam et al
[44] with minor modifications as detailed previously [31]. Details
for western blotting analysis and electrophoretic mobility shift
assays were given in Niehof and Borlak, 2005 [31]. Antibodies
directed against HNF4a (sc-6556), HNF1a (sc-6547), and Actin
(sc-1616) were purchased from Santa Cruz Biotechnology
(Heidelberg, Germany). Nuclear extracts were prepared mainly
in triplicate and used as described in the figure legend. The
antigen-antibody complexes were visualized using the enhanced
chemiluminescence (ECL) detection system (PerkinElmer Life
Sciences, Rodgau-Juegesheim, Germany). Light signal detection
was done with the CCD camera Imager system Kodak IS 440 CF
(Kodak, Biostep GmbH, Jahnsdorf, Germany) and quantification
was performed using the Kodak 1D Image analysis software
(version 3.5.). The oligonucleotides were purchased from MWG
Biotech (Ebersberg/Muenchen, Germany) with the following
sequences: AAG GCT GAA GTC CAA AGT TCA GTC CCT
TC (HNF1a, NM_000545), TGT CTA GGC CAA AGT CCT
Table 3. HNF4a gene expression in Caco-2 cells after
tacrolimus treatment.
Gene Treatment Mean6SD p-value
HNF4a Control 1.37360.347
Tacrolimus 1.16660.127 0.5127
Gene expression was measured by real time qRT-PCR in Caco-2 cells 72 h after
treatment with 25 mM( 2 0mg/ml) tacrolimus (Astellas Pharma GmbH, Munich,
Germany) (n=3, respectively) and was determined relative to expression of
mitATPase6, which served as a housekeeping gene. Non-parametric Mann-
Whitney-U-Test was used to compare tacrolimus treated and control groups.
Results are considered significant at p,0.05.
doi:10.1371/journal.pone.0004662.t003
Figure 2. Cyclosporine inhibits HNF1a to the P2 promoter of HNF4a. (A) Electrophoretic mobility shift assays with 2,5 mg Caco-2 cell nuclear
extract [control or cyclosporine treatment, 25 mM (30 mg/ml) for 72 h] and
32P labeled oligonucleotides to probe for DNA binding to the HNF1a
binding-site within the HNF4a P2 promoter (HNF1-site in HNF4a P2). In EMSA supershift assays an antibody directed against HNF1a was added.
Control and treated probes were run on same gels. (B) Dried EMSA gels were analyzed with a Molecular Imager (BioRad) using the Quantity One
software (BioRad). HNF1a binding of control extracts was set to 100% and inhibition of binding after treatment with cyclosporine [25 mM (30 mg/ml)
for 72 h] was quantified.
doi:10.1371/journal.pone.0004662.g002
Table 4. HNF4a gene expression in different beta cell lines.
Beta cell line Species Gene % Expression
INS-1E Rat HNF4a 25.03967.968
RIN-m5F Rat HNF4a 1.28960.071
MIN6 Mouse HNF4a 0.09460.026
HNF4a gene expression was measured by real time qRT-PCR in INS-1E, Rin-m5F
or MIN6 cells after 6 days in culture (n=3, respectively). Gene expression was
determined relative to expression of mitATPase6, which served as a
housekeeping gene. Gene expression in untreated liver was set to 100% and
values for gene expression in beta cells were calculated respectively.
doi:10.1371/journal.pone.0004662.t004
HNF4alpha and Cyclosporine
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TGC CAA AGG GCA GTA CT (GK, glycerol kinase,
NM_203391), AGA TGA GGG CAG AGA GCA GGC CG
(PKLR, pyruvate kinase, NM_000298), ACA AAA GTA CAA
AGG TTA AAA GA (ALDOB, aldolase B, NM_000035), GAC
AAA CAG CAA AGT CCA GGG GT (INS2, insulin 2,
NM_019130), GAC TGG TTA CTC TTT AAC GTA TC
(HNF1-site in HNF4a, NM_001030004), and CCC TCC TTT
TTT CCT CTG CCC CT [NFAT-site (nuclear factor of
activated T-cells) in HNF4a, NM_001030004] and were
32P-
labeled. Super shift assays were done with HNF4a specific
antibody (sc-6556x), HNF1a specific antibody (sc-6547x), and
NFAT specific antibody (sc-1149x), all were purchased from Santa
Cruz Biotechnology, Heidelberg, Germany and once again details
are given in [31].
RT-PCR and real-time semi-quantitative PCR
Total RNA was isolated using the nucleospin RNA Isolation Kit
(Macherey-Nagel) according to the manufacturers recommenda-
tions. 4 mg total RNA from each sample was used for reverse
transcription (Omniscript Reverse Transcriptase, Qiagen, Hilden,
Figure 3. Cyclosporine inhibits binding of HNF4a at targeted gene promoters in INS-1E cells. (A) Cell viability of INS-1E cells after multiple
treatments with cyclosporine for 72 h. (B) Actin western blotting of 10 mg INS-1E cell nuclear extracts [control or cyclopsorin treatment, 10 mg/mL
(8.3 mM) for 72 h]. (C) Electrophoretic mobility shift assays with 20 mg INS-1E cell nuclear extract [control or cyclosporine treatment, 8.3 mM (10 mg/
ml) for 72 h] and
32P labeled oligonucleotide to probe for DNA binding to the HNF4a binding-site within the promoter of HNF1a (HNF1a). In EMSA
supershift assays an antibody directed against HNF4a (+) was added. Shifted (HNF4a) and supershifted bands (HNF4a ss) were marked. (D) Dried
EMSA gels were analyzed with a Molecular Imager (BioRad) using the Quantity One software (BioRad). HNF4a binding of control extracts was set to
100% and inhibition of binding after treatment with cyclosporine [8.3 mM (10 mg/ml) for 72 h] was quantified.
doi:10.1371/journal.pone.0004662.g003
Table 5. Regulation of gene expression in INS-1E cells after
cyclosporine treatment.
Gene Treatment Mean6SD % of the control p-value
HNF4a Control 0.84960.308
Cyclosporine 0.98460.066 0.5127
INS1 Control 0.12860.003
Cyclosporine 0.08760.004 68.0 0.0495
INS2 Control 1.07660.237
Cyclosporine 0.33560.039 31.3 0.0495
Gene expression was measured by real-time qRT-PCR in INS-1E cells 72 h after
treatment with 8.3 mM( 1 0mg/ml) cyclosporine (n=3, respectively) and was
determined relative to expression of mitATPase6, which served as a
housekeeping gene. Gene expression in untreated INS-1E cells was set to 100
and values for cyclosporine treatment represent transcript abundance relative
to control. Non-parametric Mann-Whitney-U-Test was used to compare
cyclosporine treated and control groups. Results are considered significant at
p,0.05 (gene names and p-values in bold).
doi:10.1371/journal.pone.0004662.t005
HNF4alpha and Cyclosporine
PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e4662Germany). PCR was done in a mixture containing a cDNA
equivalent to 25 ng of total RNA, 1 mM of each primer, 0.25 mM
dNTP mixture, 0.625 U Thermostart-Taq (Abgene, Hamburg,
Germany) and 16PCR-buffer (Abgene, with 1.5 mM MgCl2)i na
total volume of 20 ml. PCR-reactions were carried out with a
thermocycler (T3, Biometra, Go ¨ttingen, Germany) with the
following conditions: initial denaturation at 95uC for 15 min
(Thermostart activation), denaturation at 94uC for 30 sec,
annealing at different temperatures for 45 sec (see below),
extension at 72uC for 45 sec, final extension at 74uC for 10 min.
The following primer pairs were used: HNF4a (human,
NM_000457), fwd: CTG CTC GGA GCC ACA AAG AGA
TCC ATG, rev: ATC ATC TGC CAC GTG ATG CTC TGC A
(50uC, 29cyc); HNF1a (human, NM_000545), fwd: TCT ACA
ACT GGT TTG CCA ACC, rev: GGC TTC TGT ACT CAG
CAG GC (50uC, 33cyc); ApoC2 (apolipoprotein C2) (human,
NM_000483), fwd: CCT CCC AGC TCT GTT TCT TG, rev:
GCT GCT GTG CTT TTG CTG TA (60uC, 38cyc); GK
(glycerol kinase) (human, NM_203391), fwd: AGT CTC GAA
CCC GAG GAT TT, rev: GTC ATG CAG CAA GTG GCT TA
(55uC, 36cyc); PKLR (pyruvate kinase) (human, NM_000298),
fwd: GTG GAG AGC TTT GCA GGT TC, rev: GCC GAT
TTT CTG GAC CAC TA (55uC, 36cyc); ALDOB (aldolase B)
Figure 4. Gene expression of HNF4a in liver of human patients. Gene expression was determined by real-time qPCR in n=14 patients.
Characteristics of patients are given in Table 7.
doi:10.1371/journal.pone.0004662.g004
Table 6. HNF4a isoform expression in INS-1E cells.
HNF4a isoform Mean6SD
HNF4aP1 0
HNF4aP2 418.186225.99
HNF4a isoform expression was measured by real time qRT-PCR in INS-1E cells
after 6 days in culture (n=3, respectively). Gene expression was determined
relative to expression of mitATPase6, which served as a housekeeping gene.
Gene expression in rat liver served as positive control for HNF4aP1 expression,
gene expression in rat pancreas served as positive control for HNF4aP2
expression.
doi:10.1371/journal.pone.0004662.t006
Figure 5. Cyclosporine inhibits NFAT binding to the P2 promoter of HNF4a. (A) Electrophoretic mobility shift assays with 2,5 mg Caco-2 cell
nuclear extract [control or cyclosporine treatment, 25 mM (30 mg/ml) for 72 h] and
32P labeled oligonucleotides to probe for DNA binding to the
NFAT binding site within the HNF4a P2 promoter (NFAT-site in HNF4a P2). In EMSA supershift assays an antibody directed against NFAT was added.
Control and treated probes were run on same gels. (B) Dried EMSA gels were analyzed with a Molecular Imager (BioRad) using the Quantity One
software (BioRad). NFAT binding of control extracts was set to 100% and inhibition of binding after treatment with cyclosporine [25 mM (30 mg/ml)
for 72 h] was quantified.
doi:10.1371/journal.pone.0004662.g005
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CC, rev: CCA GAA GAA CCC GTG TGA AC (50uc, 38cyc);
ALDH2 (aldehyde dehydrogenase 2) (human, NM_000690), fwd:
TGA AGG GGA CAA GGA AGA TG, rev: ACA GGT TCA
TGG CGT GTG TA (58uC, 33cyc); PCK1 (phosphoenolpyruvate
carboxykinase) (human, NM_002591), fwd: TCA GGC GGC
TGA AGA AGT AT, rev: ACG TAG GGT GAA TCC GTC AG
(60uC, 40cyc); NFAT (nuclear factor of activated T-cells) c1
(human, NM_172389), fwd: AGA AAG CGA AGC CAG TAC
CA, rev: GAG AAA GGT CGT GGA GCT TG (60uC, 40cyc);
NFATc2 (human, NM_012340), fwd: CAC GGG GCA GAA
CTT TAC AT, rev: GCA GAT CAG AGT GGG GTC AT
(60uC, 32cyc); NFATc3 (human, NM_173164), fwd: CTC AGT
GGG AGG TAG AAG GG, rev: TGT TTG TGG GAT GGA
GCA AA (60uC, 34cyc); NFATc4 (human, NM_004554), fwd:
CCA GAC TCC AAG GTG GTG TT, rev: CTG GGT GGT
GAG AAG TCC AT (60uC, 38cyc); calcineurin (PPP3R1)
(human, NM_000945), fwd: CTC ACA CTT TGA TGC GGA
TG, rev: TTG TTC CCC ACC ATC ATC TT (50uC, 32cyc);
mitATPase (human, NC_001807), fwd: CTA AAG GAC GAA
CCT GA, rev: TGG CCT GCA GTA ATG TT (55uC, 25cyc).
Real-time RT-PCR measurement was done with the Light-
cycler (Roche Diagnostics, Mannheim, Germany) with the
following conditions: denaturation at 94uC for 120 sec, annealing
at different temperatures for 8 sec (see below), extension at 72uC
for different times (see below), fluorescence at different tempera-
tures (see below). The PCR reaction was stopped after a total of
40–45 cycles and at the end of each extension phase, fluorescence
was observed and used for quantification within the linear range of
amplification. Exact quantification was achieved by serial
dilution with cDNA produced from total RNA extracts using
1:5 dilution steps. Gene expression levels were normalized to
cyclophilin, which was found to be stably expressed. The
following primer pairs were used: HNF4a (rat, NM_022180),
fwd: GCC TGC CTC AAA GCC ATC AT, rev: GAC CCT
C C AA G CA G CA T CT C( 5 5 uC, 11 sec, 88uC); HNF4aP1 (rat,
D10554), fwd: AAA TGT GCA GGT GTT GAC CA, rev: CAC
GCT CCT CCT GAA GAA TC (60uC, 7 sec, 87uC); HNF4aP2
(rat, AF329936), fwd: CTC CAG TGG CGA GTC CTT AT,
rev: TCA CGC TCC TCC TGA AGA AT (60uC, 7 sec, 87uC);
HNF4a (mouse, NM_008261), fwd: ACA CGT CCC CAT
CTG AAG, rev: CTT CCT TCT TCA TGC CAG (68uC,
12 sec, 86uC); PCK1 (rat, NM_198780), fwd: ACG CCA TTA
AGA CCA TCC AG, rev: TTC GTA GAC AAG GGG GAC
AC (60uC, 13 sec, 87uC); INS1 (rat, NM_019129), fwd: AGA
CCA TCA GCA AGC AGG TC, rev: CCA GTT GGT AGA
GGG AGC AG (68uC, 14 sec, 88uC); INS2 (rat, NM_019130),
fwd: CAG CAC CTT TGT GGT TCT CA, rev: CAG TGC
CAA GGT CTG AAG GT (60uC, 7 sec, 87uC); cyclophilin rat,
NM_017101), fwd: TTT CGT GCT CTG AGC ACT GG, rev:
CTT GCC ATT CCT GGA CCC AA (55uC, 15 sec, 82uC);
mitATPase (rat, NC_001807), fwd: CTA AAG GAC GAA
CCT GA, rev: TGG CCT GCA GTA ATG TT (55 Cu,1 3s e c ,
83uC).
Statistical analysis
All values are expressed as mean6standard deviation. To
determine significance between two groups, comparison was made
using the non-parametric two-tailed Mann-Whitney-U-Test.
Therefore, Statistica software, version 7.1 (StatSoft) was used.
The results are considered significant when the p value was less
than 0.05.
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Table 7. Patient characteristics.
Patient Identification Sex Age Tissue Information
P1 F 40 Healthy tissue from liver resection Colorectal liver metastasis
P2 M 42 Colorectal liver metastasis
P3 F 48 Colorectal liver metastasis
P4 F 61 Colorectal liver metastasis
P5 F 61 Colorectal liver metastasis
P6 M 67 Hepatocellular carcinoma
P7 F 70 Hepatocellular carcinoma
P8 F 57 Hepatocellular carcinoma
P9 M 67 Hepatocellular carcinoma
P10 M 67 Liver metastasis, stomach cancer
P11 M 72 Liver metastasis, gastrointestinal stromal tumor
P12 M 69 Colorectal liver metastasis
P13 M 76 Hepatocellular carcinoma
P14 F 57 Epitheloidal angiolipoma
Patient material was used with a permission from the ethics committee of the Medical School Hannover, Germany.
doi:10.1371/journal.pone.0004662.t007
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